Buscador de publicaciones<< Volver
Moreno R, García E, Teles R, Rumoroso JR, Cyrne Carvalho H, Goicolea FJ, Moreu J, Mauri J, Sabaté M, Mainar V, Patricio L, Valdés M, Fernández Vázquez F, Sanchez-Recalde A, Galeote G, Jimenez-Valero S, Almeida M, López De Sá E, Calvo L, Plaza I, López-Sendón JL, Martín JL
Randomized comparison of sirolimus-eluting and everolimus-eluting coronary stents in the treatment of total coronary occlusions: results from the chronic coronary occlusion treated by everolimus-eluting stent randomized trial.
Circ Cardiovasc Interv. 2013 Feb;6(1):21-8, PMID: 23403384
Patients with coronary total occlusions are at especially high risk for restenosis and new revascularizations. Sirolimus-eluting stents dramatically improved the clinical outcome of this subset of patients in randomized trials, but other drug-eluting stents, mainly the everolimus-eluting stent (currently the most frequently used stent), have not yet been evaluated in patients with coronary total occlusions. The objective was to compare the second-generation everolimus-eluting stent with the first-generation sirolimus-eluting stent in patients with coronary total occlusions.
CARDIAC & CARDIOVASCULAR SYSTEMS
Una iniciativa de
